To investigate the efficacy and safety of ethyl eicosapentaenoate in Chinese patients with severe hypertriglyceridemia. (1) Efficacy The change rate of serum TG after taking the test drug for 12 weeks compared with before taking the drug (2) Safety Adverse events occurring during administration
To evaluate the pharmacokinetics of single oral doses of 900 mg, 1800 mg, or 2700 mg of eicosapentaenoate ethyl ester, and multiple oral doses of 1800 mg or 3600 mg daily in two divided doses for 8 days in healthy Chinese adult men learning and safety.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.